Deal Details
Follow-on Offering
Summary
Baird served as co-manager on this offering
About
PPD, Inc. (“PPD” or the “Company”) (NASDAQ-GS: PPD) recently completed an underwritten public offering of 43,700,000 shares of its common stock at a price to the public of $32.25 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 5,700,000 shares of common stock. Certain stockholders of the Company participated in this offering, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group, Inc. The gross proceeds to PPD’s selling stockholders from the offering are expected to be approximately $1.409 billion.PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. PPD’s customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 24,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. PPD, Inc. is headquartered in Wilmington, North Carolina.
CONTACT US TO LEARN MORE
- Date
- September 2020
- Company
- PPD, Inc.
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
